表紙
市場調査レポート

性器疣贅 (尖圭コンジローム):パイプライン製品の分析

Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 200950
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
性器疣贅 (尖圭コンジローム):パイプライン製品の分析 Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2016
出版日: 2016年04月30日 ページ情報: 英文 70 Pages
概要

性器疣贅 (尖圭コンジローマ) はもっとも一般的な性行為感染症の一種です。性的活動に積極的な人々の半数以上が一生のある時点で、性器疣贅を引き起こすウイルスに感染するものと思われています。名前が示すとおり、性器疣贅は性器の湿った組織に作用します。性器疣贅の外見は、小さな肉色のこぶの形 (またはカリフラワー状の外形) をしています。多くの場合、こぶは非常に小さく、肉眼では見ることができません。

当レポートでは、世界各国での性器疣贅 (尖圭コンジローム) 治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

性器疣贅 (尖圭コンジローム)の概要

治療薬の開発

  • パイプライン製品の概要

性器疣贅 (尖圭コンジローム):企業で開発中の治療薬

性器疣贅 (尖圭コンジローム):パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

性器疣贅 (尖圭コンジローム):企業で開発中の製品

性器疣贅 (尖圭コンジローム)の治療薬開発に従事している企業

  • Agilvax, Inc.
  • Aviragen Therapeutics, Inc.
  • Biogenomics Limited
  • BioMAS Ltd.
  • Foamix Pharmaceuticals Ltd.
  • G&E Herbal Biotechnology Co., Ltd.
  • Helix BioPharma Corp.
  • Laboratories Ojer Pharma S.L.
  • LEO Pharma A/S
  • Novan, Inc.
  • Novartis AG
  • Tamir Biotechnology, Inc.
  • Zydus Cadila Healthcare Limited

性器疣贅 (尖圭コンジローム):治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

性器疣贅 (尖圭コンジローム):最近のパイプライン動向

性器疣贅 (尖圭コンジローム):休止中のプロジェクト

性器疣贅 (尖圭コンジローム):開発が中止された製品

性器疣贅 (尖圭コンジローム):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8046IDB

Summary

Global Markets Direct's, 'Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2016', provides an overview of the Genital Warts (Condylomata Acuminata) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Genital Warts (Condylomata Acuminata), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Genital Warts (Condylomata Acuminata) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Genital Warts (Condylomata Acuminata)
  • The report reviews pipeline therapeutics for Genital Warts (Condylomata Acuminata) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Genital Warts (Condylomata Acuminata) therapeutics and enlists all their major and minor projects
  • The report assesses Genital Warts (Condylomata Acuminata) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Genital Warts (Condylomata Acuminata)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Genital Warts (Condylomata Acuminata)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Genital Warts (Condylomata Acuminata) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Genital Warts (Condylomata Acuminata) Overview
  • Therapeutics Development
    • Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview
  • Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies
  • Genital Warts (Condylomata Acuminata) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Genital Warts (Condylomata Acuminata) - Products under Development by Companies
  • Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development
    • Agilvax, Inc.
    • Aviragen Therapeutics, Inc.
    • Biogenomics Limited
    • BioMAS Ltd.
    • Foamix Pharmaceuticals Ltd.
    • G&E Herbal Biotechnology Co., Ltd.
    • Helix BioPharma Corp.
    • Laboratories Ojer Pharma S.L.
    • LEO Pharma A/S
    • Novan, Inc.
    • Novartis AG
    • Tamir Biotechnology, Inc.
    • Zydus Cadila Healthcare Limited
  • Genital Warts (Condylomata Acuminata) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (cervical cancer + genital warts) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AS-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AX-03 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BTA-074 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • imiquimod - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • imiquimod SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ingenol mebutate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • interferon alfa-2b - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • interferon alpha-2b (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LFX-453 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PP-210 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ranpirnase - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-206 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SRT-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Genital Warts (Condylomata Acuminata) - Recent Pipeline Updates
  • Genital Warts (Condylomata Acuminata) - Dormant Projects
  • Genital Warts (Condylomata Acuminata) - Discontinued Products
  • Genital Warts (Condylomata Acuminata) - Product Development Milestones
    • Featured News & Press Releases
      • Dec 22, 2011: Helix BioPharma Files Clinical Trial Applications For Phase III Efficacy Trial Of Topical Interferon Alpha-2b In Patients With Low-Grade Cervical Lesions
      • Jun 08, 2010: Helix BioPharma Corp Announces Phase II Clinical Trial Results of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
      • Mar 22, 2010: Helix BioPharma Corp Achieves Last-Patient-Out In Its Phase II Trial Of Topical Interferon Alpha-2b In Patients With Ano-Genital Warts
      • Sep 22, 2008: Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Genital Warts (Condylomata Acuminata), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Agilvax, Inc., H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Aviragen Therapeutics, Inc., H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Biogenomics Limited, H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by BioMAS Ltd., H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Helix BioPharma Corp., H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Laboratories Ojer Pharma S.L., H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by LEO Pharma A/S, H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Novan, Inc., H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Novartis AG, H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Tamir Biotechnology, Inc., H1 2016
  • Genital Warts (Condylomata Acuminata) - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Genital Warts (Condylomata Acuminata) Therapeutics - Recent Pipeline Updates, H1 2016
  • Genital Warts (Condylomata Acuminata) - Dormant Projects, H1 2016
  • Genital Warts (Condylomata Acuminata) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Genital Warts (Condylomata Acuminata), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top